Qyuro F & B Co., Ltd. announced that it expects to receive KRW 5.4 billion in funding from CUROCOM Co.,Ltd. and other investors
July 27, 2020
Share
Qyuro F & B Co., Ltd. announced a private placement of 10,800,000 common shares having face value of KRW 500 at an issue price of KRW 500 for the gross proceeds of KRW 5,400,000,000 on July 27, 2020. The company will raise funding through shareholder allocation method. The shares are allocated per share for 6.5219% stake in the company. The transaction is expected to close on July 29, 2020. Post-closing, the total number of shares issued will increase from 1,655,968 shares to 12,455,968 shares. The transaction has been approved by the board of directors of the company. CUROCOM Co.,Ltd. (KOSDAQ:A040350) holding 39.32% stake in the company will subscribe for 4,247,020 shares.
CreoSG Co Ltd, formerly Curocom Co Ltd, is a Korea-based company mainly engaged in solution business and distribution business. The Company operates through three segments. The Solutions Business segment is engaged in the development and provision of financial consulting and software for financial institutions. Additionally, the segment is engaged in the supply of core banking solutions BANCS-K framework and BANCS-K Package to banks and other financial institutions. The Distribution Business segment is engaged in the distribution business of computers, laptops, printers, and multi-function printers. The New Drug and Vaccine Development Business segment is engaged in the development of vaccines for acquired immunodeficiency syndrome(AIDS), corona virus disease 19 (COVID-19) vaccine and other infectious diseases, and research and development of super antibiotics for Staphylococcus aureus.
CREOSG CO.,LTD. 
